Landscape Capital Management, L.L.C. Uni Qure N.V. Transaction History

Landscape Capital Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$27.39 - $68.41 $385,486 - $962,802	-14,074 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$22.8 - $33.93 $255,930 - $380,864	-11,225 Reduced 44.37%	14,074 $406,000
Q3 2018 Nov 14, 2018	BUY	$29.75 - $43.08 $752,645 - $1.09 Million	25,299 New	25,299 $921,000
Q1 2018 May 11, 2018	SELL	$17.1 - $26.61 $189,143 - $294,333	-11,061 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$9.47 - $19.59 $126,225 - $261,115	-13,329 Reduced 54.65%	11,061 $217,000
Q3 2017 Nov 14, 2017	SELL	$7.7 - $9.6 $105,205 - $131,164	-13,663 Reduced 35.91%	24,390 $234,000
Q2 2017 Aug 14, 2017	BUY	N/A	38,053	38,053 $236,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Landscape Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Landscape Capital Management, L.L.C. with notifications on news.